My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 111

    1.

    Kremezin (AST-120) delays the progression of diabetic nephropathy in Japanese type 2 diabetic patients.

    Shimizu H, Okada S, Shinsuke OI, Mori M.

    Diabetes Care. 2005 Oct;28(10):2590. No abstract available. PMID: 16186309 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Protective effect of an oral adsorbent on renal function in chronic renal failure: determinants of its efficacy in diabetic nephropathy.

    Sanaka T, Akizawa T, Koide K, Koshikawa S.

    Ther Apher Dial. 2004 Jun;8(3):232-40.PMID: 15154877 [PubMed - indexed for MEDLINE]Related articles

    3.

    Effects of oral adsorbent AST-120 in patients with chronic renal failure with or without diabetes.

    Nakamura T, Kawagoe Y, Ueda Y, Ebihara I, Koide H.

    Ren Fail. 2004 Jan;26(1):99-101. No abstract available. PMID: 15083931 [PubMed - indexed for MEDLINE]Related articles

    4.

    Oral administration of AST-120 (Kremezin) is a promising therapeutic strategy for advanced glycation end product (AGE)-related disorders.

    Yamagishi S, Nakamura K, Matsui T, Inoue H, Takeuchi M.

    Med Hypotheses. 2007;69(3):666-8. Epub 2007 Feb 28.PMID: 17331665 [PubMed - indexed for MEDLINE]Related articles

    5.

    AST-120 (Kremezin) initiated in early stage chronic kidney disease stunts the progression of renal dysfunction in type 2 diabetic subjects.

    Konishi K, Nakano S, Tsuda S, Nakagawa A, Kigoshi T, Koya D.

    Diabetes Res Clin Pract. 2008 Sep;81(3):310-5. Epub 2008 Jun 11.PMID: 18550198 [PubMed - indexed for MEDLINE]Related articles

    6.

    The telmisartan renoprotective study from incipient nephropathy to overt nephropathy--rationale, study design, treatment plan and baseline characteristics of the incipient to overt: angiotensin II receptor blocker, telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) Study.

    Makino H, Haneda M, Babazono T, Moriya T, Ito S, Iwamoto Y, Kawamori R, Takeuchi M, Katayama S.

    J Int Med Res. 2005 Nov-Dec;33(6):677-86.PMID: 16372586 [PubMed - indexed for MEDLINE]Related articles

    7.

    [Diabetic nephropathy and ACE inhibitors]

    Amann B.

    Clin Res Cardiol. 2006 Jan;95 Suppl 1:i83-7. German. PMID: 16598556 [PubMed - indexed for MEDLINE]Related articles

    8.

    The application of synthetic hANP in diabetic nephropathy with nephrotic syndrome.

    Kikumoto Y, Wada J, Makino H.

    Diabetes Care. 2006 Jan;29(1):172-3. No abstract available. PMID: 16373924 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Effect of oral adsorbent on the progression of diabetic nephropathy.

    Okada K, Shibahara H, Takahashi S.

    Nephron. 1997;76(4):489-90. No abstract available. PMID: 9274851 [PubMed - indexed for MEDLINE]Related articles

    10.

    Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study.

    Kurokawa K, Chan JC, Cooper ME, Keane WF, Shahinfar S, Zhang Z.

    Clin Exp Nephrol. 2006 Sep;10(3):193-200.PMID: 17009077 [PubMed - indexed for MEDLINE]Related articles

    11.

    [J-MIND study: effect of nifedipine on renal function in Japanese hypertensive patients with diabetes mellitus]

    Yoshino G.

    Drugs. 2006;66 Spec No 1:22-4. Review. Japanese. Erratum in: Drugs. 2007;67(13):1849. PMID: 18200775 [PubMed - indexed for MEDLINE]Related articles

    12.

    Irbesartan: a review of its use in hypertension and diabetic nephropathy.

    Croom KF, Plosker GL.

    Drugs. 2008;68(11):1543-69. Review.PMID: 18627212 [PubMed - indexed for MEDLINE]Related articles

    13.

    A multicenter, randomized, double-blind, placebo-controlled, dose-ranging study of AST-120 (Kremezin) in patients with moderate to severe CKD.

    Schulman G, Agarwal R, Acharya M, Berl T, Blumenthal S, Kopyt N.

    Am J Kidney Dis. 2006 Apr;47(4):565-77.PMID: 16564934 [PubMed - indexed for MEDLINE]Related articles

    14.

    Diet therapy in diabetic nephropathy.

    Maeda Y, Shiigai T.

    Contrib Nephrol. 2007;155:50-8. Review.PMID: 17369713 [PubMed - indexed for MEDLINE]Related articles

    15.

    Nephropathy in type 2 diabetes.

    Mora C, Garcia J, Navarro JF.

    N Engl J Med. 2000 Feb 10;342(6):441; author reply 442. No abstract available. PMID: 10681230 [PubMed - indexed for MEDLINE]Related articles

    16.

    The role of sulodexide in the treatment of diabetic nephropathy.

    Weiss R, Niecestro R, Raz I.

    Drugs. 2007;67(18):2681-96. Review.PMID: 18062718 [PubMed - indexed for MEDLINE]Related articles

    17.

    Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy.

    Nakamura T, Sugaya T, Kawagoe Y, Ueda Y, Osada S, Koide H.

    Diabetes Care. 2005 Nov;28(11):2728-32.PMID: 16249547 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    [Cost-effectiveness of angiotensin receptor blockers in patients with type 2 diabetes mellitus and nephropathy in Israel]

    Berar-Yanay N, Leshno M, Hertzeanu L, Weintrob N.

    Harefuah. 2008 Mar;147(3):211-5, 278. Hebrew. PMID: 18488861 [PubMed - indexed for MEDLINE]Related articles

    19.

    Albuminuria: a target for treatment of type 2 diabetic nephropathy.

    de Zeeuw D.

    Semin Nephrol. 2007 Mar;27(2):172-81. Review.PMID: 17418686 [PubMed - indexed for MEDLINE]Related articles

    20.

    Diabetic nephropathy: introduction.

    Breyer MD.

    Semin Nephrol. 2007 Mar;27(2):129. No abstract available. PMID: 17418681 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity